JP6078067B2 - 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用 - Google Patents

炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用 Download PDF

Info

Publication number
JP6078067B2
JP6078067B2 JP2014528563A JP2014528563A JP6078067B2 JP 6078067 B2 JP6078067 B2 JP 6078067B2 JP 2014528563 A JP2014528563 A JP 2014528563A JP 2014528563 A JP2014528563 A JP 2014528563A JP 6078067 B2 JP6078067 B2 JP 6078067B2
Authority
JP
Japan
Prior art keywords
cells
hdl
hif
mice
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014528563A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014526440A5 (enExample
JP2014526440A (ja
Inventor
ロビン ファリアス‐アイスナー
ロビン ファリアス‐アイスナー
シュリニヴァーサ ティー． レディ
シュリニヴァーサ ティー． レディ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
University of California Berkeley
Original Assignee
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California San Diego UCSD filed Critical University of California San Diego UCSD
Publication of JP2014526440A publication Critical patent/JP2014526440A/ja
Publication of JP2014526440A5 publication Critical patent/JP2014526440A5/ja
Application granted granted Critical
Publication of JP6078067B2 publication Critical patent/JP6078067B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2014528563A 2011-08-29 2012-08-29 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用 Expired - Fee Related JP6078067B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161528447P 2011-08-29 2011-08-29
US61/528,447 2011-08-29
US201261624333P 2012-04-15 2012-04-15
US61/624,333 2012-04-15
US201261646772P 2012-05-14 2012-05-14
US61/646,772 2012-05-14
PCT/US2012/052925 WO2013033260A1 (en) 2011-08-29 2012-08-29 Use of hdl-related molecules to treat and prevent proinflammatory conditions

Publications (3)

Publication Number Publication Date
JP2014526440A JP2014526440A (ja) 2014-10-06
JP2014526440A5 JP2014526440A5 (enExample) 2016-02-12
JP6078067B2 true JP6078067B2 (ja) 2017-02-08

Family

ID=47756845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014528563A Expired - Fee Related JP6078067B2 (ja) 2011-08-29 2012-08-29 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用

Country Status (8)

Country Link
US (2) US9241976B2 (enExample)
EP (1) EP2751126B1 (enExample)
JP (1) JP6078067B2 (enExample)
KR (1) KR20140063747A (enExample)
CN (1) CN104039810A (enExample)
AU (1) AU2012301955A1 (enExample)
CA (1) CA2846865A1 (enExample)
WO (1) WO2013033260A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10426817B2 (en) 2017-01-24 2019-10-01 Macregen, Inc. Treatment of age-related macular degeneration and other eye diseases with apolipoprotein mimetics
WO2018190896A1 (en) * 2017-04-13 2018-10-18 Lipimetix Development, Inc. Apoe mimetic peptide compositions
CN120085016A (zh) * 2025-03-14 2025-06-03 北京大学第三医院（北京大学第三临床医学院） 一种apoa1作为生物标志物在制备用于监测结肠炎症活动度的产品中的应用

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
DK145385D0 (da) 1985-03-29 1985-04-01 Novo Industri As Monoklonalt antistof til immunkemisk analyse
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US4777127A (en) 1985-09-30 1988-10-11 Labsystems Oy Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5114863A (en) 1986-09-30 1992-05-19 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Immunosorbant assay for α-1-antitrypsin, kit employing said assay, monoclonal antibody to α-1-antitrypsin, and hybridoma for producing said monoclonal antibody
GB8702816D0 (en) 1987-02-07 1987-03-11 Al Sumidaie A M K Obtaining retrovirus-containing fraction
WO1989001973A2 (en) 1987-09-02 1989-03-09 Applied Biotechnology, Inc. Recombinant pox virus for immunization against tumor-associated antigens
AP129A (en) 1988-06-03 1991-04-17 Smithkline Biologicals S A Expression of retrovirus gag protein eukaryotic cells
EP1001032A3 (en) 1989-08-18 2005-02-23 Chiron Corporation Recombinant retroviruses delivering vector constructs to target cells
SE8904007D0 (sv) 1989-11-28 1989-11-28 Ferring Ab Monoklona antikroppar och diagnostiseringsmetod
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
RU2152787C2 (ru) * 1994-06-02 2000-07-20 Дан Рига Лекарство против стресса, против снижения уровня активности и против старения и способ его получения
US20030027216A1 (en) 2001-07-02 2003-02-06 Kiernan Urban A. Analysis of proteins from biological fluids using mass spectrometric immunoassay
US5891641A (en) 1997-02-21 1999-04-06 The Regents Of The University Of California Assay for disease related conformation of a protein
US5955582A (en) 1997-09-26 1999-09-21 Beckman Coulter, Inc. Antibody against a 3-aminophenylboronic-glycated protein complex and its use in an immunoassay
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US20050214760A1 (en) 2002-01-07 2005-09-29 Johns Hopkins University Biomarkers for detecting ovarian cancer
US6930085B2 (en) 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
AU2003247610A1 (en) 2002-06-21 2004-01-06 Ptc Therapeutics, Inc. METHODS FOR IDENTIFYING SMALL MOLECULES THAT MODULATE PREMATURE TRANSLATION TERMINATION AND NONSENSE MEDIATED mRNA DECAY
US7927791B2 (en) 2002-07-24 2011-04-19 Ptc Therapeutics, Inc. Methods for identifying small molecules that modulate premature translation termination and nonsense mediated mRNA decay
NZ562192A (en) 2002-08-06 2009-07-31 Ciphergen Biosystems Inc Use of biomarkers for detecting ovarian cancer
US7191068B2 (en) 2003-03-25 2007-03-13 Proteogenix, Inc. Proteomic analysis of biological fluids
JP2007504840A (ja) 2003-05-12 2007-03-08 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア Ｇｒｐ９４ベース組成物及びそれらの使用方法
EP1658497B1 (en) 2003-08-25 2008-12-03 Marc Ramael A method and kit for the quantitative and/or qualitative detection of components in a sample
US20070031379A1 (en) 2004-01-09 2007-02-08 Lee Kyu H Therapeutic agent for treatment of cancer comprising human apolipoprotein (a) kringles lk68 or lk8 genes as effective ingredient, and method for treating cancer using the same
US20060147946A1 (en) 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
WO2005093413A2 (en) 2004-03-22 2005-10-06 Yale University Diagnosis and treatment of preeclampsia
US9488655B2 (en) 2004-07-14 2016-11-08 The Regents Of The University Of California Biomarkers for detection of early- and late-stage endometrial cancer
US7670792B2 (en) 2004-07-14 2010-03-02 The Regents Of The University Of California Biomarkers for early detection of ovarian cancer
US9487575B2 (en) * 2004-07-14 2016-11-08 The Regents Of The University Of California Compositions and methods for treatment of gynecologic cancers
EP1789805B1 (en) 2004-07-14 2010-09-15 The Regents of The University of California Biomarker for early detection of ovarian cancer
EP1796708A4 (en) * 2004-09-02 2009-07-08 Cognosci Inc IMPROVED APO-E ANALOGS AND USE METHOD THEREFOR
JP2008513031A (ja) 2004-09-20 2008-05-01 プロテオジェニックス， インコーポレイテッド 胎児異数性の診断
NZ555826A (en) * 2004-12-06 2009-11-27 Univ California Methods for improving the structure and function of arterioles
US7427662B2 (en) 2005-02-01 2008-09-23 Baord Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein A-I and high density lipoprotein
KR101310000B1 (ko) 2005-03-11 2013-09-25 싸이퍼젠 바이오시스템즈, 인코포레이티드 난소암 및 자궁내막암에 대한 바이오마커 : 헵시딘
US20080293639A1 (en) 2005-04-29 2008-11-27 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
EP2269623A1 (en) * 2005-04-29 2011-01-05 The Regents of The University of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7604948B2 (en) 2005-05-05 2009-10-20 The Regents Of The University Of California Biomarkers for diagnosing an autism spectrum disorder
US20100173788A1 (en) 2005-06-21 2010-07-08 Vermillion, Inc. Biomarkers for breast cancer
US7575876B2 (en) 2005-10-27 2009-08-18 The University Of Washington Biomarkers for neurodegenerative disorders
EP2537525A1 (en) 2005-12-16 2012-12-26 Electrophoretics Limited Diagnosis and prognosis of colorectal cancer
KR100725642B1 (ko) * 2006-01-20 2007-06-07 충남대학교산학협력단 저밀도 지단백질에 대해 항산화성을 갖는 펩타이드
US7723045B2 (en) 2006-02-10 2010-05-25 The Regents Of The University Of California Assays to predict atherosclerosis and dysfunctional high-density lipoprotein
CA2690376A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Apoa-1 peptide mimetics
CA2704729C (en) * 2007-08-28 2020-06-23 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010537638A (ja) * 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション 合成アポリポ蛋白質ｅ模倣ポリペプチドおよび使用方法
JP2009092440A (ja) 2007-10-04 2009-04-30 Shimadzu Corp 卵巣癌の診断システム及び卵巣癌の診断方法

Also Published As

Publication number Publication date
CA2846865A1 (en) 2013-03-07
EP2751126B1 (en) 2018-03-07
CN104039810A (zh) 2014-09-10
EP2751126A1 (en) 2014-07-09
WO2013033260A1 (en) 2013-03-07
EP2751126A4 (en) 2015-11-04
KR20140063747A (ko) 2014-05-27
US20170204160A1 (en) 2017-07-20
JP2014526440A (ja) 2014-10-06
US10208103B2 (en) 2019-02-19
AU2012301955A1 (en) 2014-03-06
US20140323410A1 (en) 2014-10-30
US9241976B2 (en) 2016-01-26

Similar Documents

Publication Publication Date Title
Song et al. CREG protects from myocardial ischemia/reperfusion injury by regulating myocardial autophagy and apoptosis
CN110023332B (zh) 包含sasp调节剂和衰老衰减剂的组合物及其用于调节细胞衰老的用途
KR20210117271A (ko) 근막 손상 예방 및 치료를 위한 아넥신의 사용근각 손상 예방 및 치료를 위한 아넥신의 사용
WO2023094581A1 (en) Compositions for the treatment of glioblastoma
CN111417647A (zh) 新型senolytic肽
JP6078067B2 (ja) 炎症誘発性状態の治療および予防のためのｈｄｌ関連分子の使用
US20150202248A1 (en) E2f as a target of hormone refractory prostate cancer
US9487575B2 (en) Compositions and methods for treatment of gynecologic cancers
EP3836951A1 (en) Peptides and compositions for targeted treatment and imaging
AU2017232632A1 (en) Ephrin receptor A2 (EphA2)-targeted docetaxel-generating nano-liposome compositions
US12516085B2 (en) Methods and compositions for treating Myc-driven cancers
KR20220051418A (ko) 근위축성 측삭 경화증 치료제
CN118252913B (zh) 多肽偶联物及其在射血分数保留的心衰中的应用
TW201200151A (en) Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells
US20200031873A1 (en) Repurposing cell penetrating peptides and their novel derivatives and iopromide and iodo-aryl carbonates for treatment of senescence-related diseases and disorders
JP2019512216A (ja) カルシウムチャネルのペプチド阻害剤
US20210322508A1 (en) Peptides and compositions for targeted treatment and imaging
KR101697771B1 (ko) Itm2a 폴리펩타이드 또는 이를 암호화하는 핵산을 유효성분으로 하는 항암용 조성물
JP6175076B2 (ja) Ａｄ３６ｅ４ｏｒｆ１およびａｋｔ１阻害剤を使用した血糖コントロールの向上
JP5786266B2 (ja) アポトーシス誘導剤
EP4539871A1 (en) Method and therapeutic agent for treatment of disease or disorder associated with impaired firing rate and/or mitochondrial calcium homeostasis
KR101401894B1 (ko) Ｓｍｇ-1을 유효성분으로 함유하는 항암제 민감성 증진용 조성물
JP2006524712A (ja) カテプシンの阻害のための方法および組成物
US20080096833A1 (en) Polytpeptide Specific To Liver Cancer, Polynucleotide Coding For The Polypeptide, And Rna Molecule Inhibiting Expression Of The Polypeptide

Legal Events

Date Code Title Description
RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150527

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150827

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151217

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160525

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160822

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20161222

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170113

R150 Certificate of patent or registration of utility model

Ref document number: 6078067

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees